Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$80.55

-0.375 (-0.46%)

06:23
10/09/19
10/09
06:23
10/09/19
06:23

Sarepta selloff Monday a 'strong' buying opportunity, says Nomura Instinet

Nomura Instinet analyst Christopher Marai views the selloff Monday in shares of Sarepta Therapeutics as a "strong" buying opportunity. He keeps a Buy rating on the shares with a $230 price target.

SRPT Sarepta
$80.55

-0.375 (-0.46%)

10/04/19
PIPR
10/04/19
NO CHANGE
Target $185
PIPR
Overweight
Sarepta data 'de-risk' entire LGMD gene therapy platform, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says the nine-month functional data from three LGMD2E patients dosed with Sarepta Therapeutics' gene therapy showed improvements across all measures. The analyst found the data particularly encouraging because both older 13 year old patients with declining function showed signs of disease reversal, the four year old patient improved to "normal" on the North Star Assessment for Dysferlinopathy functional scale, and there no signs of additional safety signals after initial liver function test elevations. These data "de-risk" the entire LGMD gene therapy platform and create a possible path to accelerated approval, Brill tells investors in a research note titled "LGMD2E Gene Therapy Data Show Indisputable Functional Benefits." She keeps an Overweight rating on Sarepta shares with a $185 price target. The stock in morning trading is up 6% to $86.11.
10/04/19
HCWC
10/04/19
NO CHANGE
HCWC
Sarepta programs show gene therapy benefit, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating and $160 price target on Sarepta Therapeutics, stating in a note titled 'Muscular Dystrophy Toolbox Delivers Compelling Reads Across Programs' that "functional and biochemical improvements across SRP-9003 and SRP-9001 are suggestive of a gene therapy clinical benefit." The analyst added that the clinical benefit of canonical gene therapy programs is "becoming more incontrovertible."
10/04/19
WBLR
10/04/19
NO CHANGE
WBLR
Outperform
William Blair says new data shows Sarepta's gene therapy pipeline breadth
William Blair analyst Tim Lugo noted that Sarepta Therapeutics released the first functional data from its limb girdle muscular dystrophy-2E gene therapy trial, pointing out that SRP-9003 produced a significant improvement across all functional measures at nine months post-treatment. He views the new data as demonstrating the depth of the company's gene therapy pipeline and thinks safety results from these patients will "be of high interest for investors over the next six months," since clean safety could have a positive read-through to the four gene therapy assets to target the additional LGMD subtypes. Lugo has an Outperform rating on Sarepta shares.
10/08/19
OPCO
10/08/19
NO CHANGE
OPCO
Perform
Sarepta updates on LGMD-2E 'intriguing,' but questions remain, says Oppenheimer
Oppenheimer analyst Hartaj Singh said the nine-month functional improvements reported by Sarepta for three patients in the company's ongoing LGMD-2E Phase 1/2a trial were "intriguing," but questions still remain as to why the company changed the original protocol, whether comparing with natural history might be appropriate and if the company execute on its commercial manufacturing strategy. Singh keeps a Perform rating on Sarepta shares.

TODAY'S FREE FLY STORIES

TXN

Texas Instruments

$120.29

-8.32 (-6.47%)

11:50
10/23/19
10/23
11:50
10/23/19
11:50
Options
Aggressive post-earnings put seller in Texas Instruments »

Aggressive post-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBTC

Bitcoin Investment Trust

$0.00

(0.00%)

, FB

Facebook

$185.39

3.12 (1.71%)

11:48
10/23/19
10/23
11:48
10/23/19
11:48
Periodicals
Bitcoin falls amid Zuckerberg testimony on Facebook's Libra, Bloomberg says »

Bloomberg's Claire…

GBTC

Bitcoin Investment Trust

$0.00

(0.00%)

FB

Facebook

$185.39

3.12 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

SPY

SPDR S&P 500 ETF Trust

$299.50

0.47 (0.16%)

, SPX

S&P 500

$0.00

(0.00%)

11:47
10/23/19
10/23
11:47
10/23/19
11:47
General news
President Trump says lifting sanctions on Turkey with ceasefire to be permanent »

President Trump announced…

SPY

SPDR S&P 500 ETF Trust

$299.50

0.47 (0.16%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$41.57

0.84 (2.06%)

11:45
10/23/19
10/23
11:45
10/23/19
11:45
Options
Zscaler call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

11:45
10/23/19
10/23
11:45
10/23/19
11:45
General news
Treasury's $20 B 2-year FRN was awarded at a high discount margin of 0.300% »

Treasury's $20 B…

SDC

SmileDirectClub

$10.19

0.685 (7.21%)

11:39
10/23/19
10/23
11:39
10/23/19
11:39
Recommendations
SmileDirectClub analyst commentary  »

Guggenheim says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HEXO

Hexo

$2.54

-0.05 (-1.93%)

11:39
10/23/19
10/23
11:39
10/23/19
11:39
Hot Stocks
Breaking Hot Stocks news story on Hexo »

Hexo Corp trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 12

    Nov

  • 12

    Nov

11:37
10/23/19
10/23
11:37
10/23/19
11:37
General news
2-Yr FRN Note Auction Bid/Cover data reported »

2-Yr FRN Note Auction…

11:37
10/23/19
10/23
11:37
10/23/19
11:37
General news
2-Yr FRN Note Auction Total Amount data reported »

2-Yr FRN Note Auction…

SAVE

Spirit Airlines

$37.33

0.08 (0.21%)

, EADSY

Airbus

$0.00

(0.00%)

11:33
10/23/19
10/23
11:33
10/23/19
11:33
Periodicals
Spirit Airlines near deal for as many as 100 Airbus A320 jets, Reuters says »

Spirit Airlines (SAVE) is…

SAVE

Spirit Airlines

$37.33

0.08 (0.21%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 13

    Nov

KAMN

Kaman

$58.38

-0.2 (-0.34%)

11:33
10/23/19
10/23
11:33
10/23/19
11:33
Hot Stocks
Kaman executes long term agreement with Winglet Technology »

Kaman Composites…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

TWTR

Twitter

$38.93

0.11 (0.28%)

11:32
10/23/19
10/23
11:32
10/23/19
11:32
Earnings
Fly Intel: What to watch in Twitter earnings report »

Twitter (TWTR) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

ABMD

Abiomed

$175.20

4.45 (2.61%)

, ABT

Abbott

$81.49

0.95 (1.18%)

11:29
10/23/19
10/23
11:29
10/23/19
11:29
Recommendations
Trial for potential Abiomed competition pushed back a year, says Piper Jaffray »

This morning, the primary…

ABMD

Abiomed

$175.20

4.45 (2.61%)

ABT

Abbott

$81.49

0.95 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

HEMA

HemaCare Corp.

$0.00

(0.00%)

11:27
10/23/19
10/23
11:27
10/23/19
11:27
Periodicals
Breaking Periodicals news story on HemaCare Corp. »

HemaCare Corp. working…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$175.20

4.45 (2.61%)

, ABT

Abbott

$81.52

0.98 (1.22%)

11:27
10/23/19
10/23
11:27
10/23/19
11:27
Hot Stocks
Abiomed jumps after Abbott heart pump trial pushed back one year »

An update today on…

ABMD

Abiomed

$175.20

4.45 (2.61%)

ABT

Abbott

$81.52

0.98 (1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 13

    Nov

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

, ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26
Recommendations
MacroGenics, Zymeworks analyst commentary  »

MacroGenics price target…

MGNX

MacroGenics

$9.87

-1.17 (-10.60%)

ZYME

Zymeworks

$30.25

-0.26 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 06

    Nov

TRU

TransUnion

$82.71

2.31 (2.87%)

11:26
10/23/19
10/23
11:26
10/23/19
11:26
Conference/Events
TransUnion management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 19

    Nov

CVM

CEL-SCI

$7.35

(0.00%)

11:25
10/23/19
10/23
11:25
10/23/19
11:25
Options
Cel Sci call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCG

NRC Group

$13.00

(0.00%)

, ECOL

US Ecology

$66.75

0.245 (0.37%)

11:25
10/23/19
10/23
11:25
10/23/19
11:25
Conference/Events
US Ecology to host special shareholder meeting »

Special Shareholder…

NRCG

NRC Group

$13.00

(0.00%)

ECOL

US Ecology

$66.75

0.245 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 31

    Oct

SNAP

Snap

$13.24

-0.76 (-5.43%)

11:19
10/23/19
10/23
11:19
10/23/19
11:19
Hot Stocks
Snap says DOJ, SEC no longer pursuing investigations of IPO disclosures »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/23/19
10/23
11:17
10/23/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/23/19
10/23
11:16
10/23/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$184.34

2.07 (1.14%)

11:05
10/23/19
10/23
11:05
10/23/19
11:05
Hot Stocks
Facebook shares up 1.6% as CEO testifies on Capitol Hill »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

CNC

Centene

$48.49

-0.28 (-0.57%)

11:05
10/23/19
10/23
11:05
10/23/19
11:05
Options
Centene call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

D

Dominion

$83.07

0.29 (0.35%)

11:03
10/23/19
10/23
11:03
10/23/19
11:03
Hot Stocks
Dominion, Smithfield Foods double investment in renewable natural gas to $500M »

Dominion Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.